3 Healthcare Stocks Getting Hammered

GEMP and ONCE are two of the worst stocks on the Nasdaq today

Managing Editor
Aug 7, 2018 at 2:30 PM
facebook twitter linkedin

Stocks are vaulting higher today thanks to a fresh batch of corporate earnings. It's not all positive news, though, and stocks careening lower include biotech Gemphire Therapeutics (NASDAQ:GEMP), gene therapy specialist Spark Therapeutics Inc (NASDAQ:ONCE), and medical device maker Orthofix Medical Inc (NASDAQ:OFIX). Here's a closer look at what's driving shares of GEMP, ONCE, and OFIX today.

FDA Request Sends GEMP Stock Reeling

At last check, Gemphire Therapeutics stock was down 52.9% to trade at $3.46, the second-worst stock on the Nasdaq today, after the Food and Drug Administration (FDA) asked for more safety data concerning the company's cholesterol drug, gemcabene. A hold is placed on any further studies until that data is provided. This is easily GEMP's worst day in history, and the stock earlier hit a new record low of $3.10. 

Despite the security's historical volatility, analysts remain committed to the drugmaker. All three of the brokerages covering GEMP rate it a "buy" or "strong buy," and its average 12-month price target of $26.50 is more than triple yesterday's closing perch of $7.34. However, Raymond James just downgraded the shares to "market perform" from "outperform."

Citi Still A Fan Of ONCE Stock Despite Subpar Earnings

Spark Therapeutics stock is down a 28% to trade at $55.85, also putting it near the bottom of the Nasdaq today, after the company announced lackluster trial data for the firm's hemophilia drug. In addition, the drug company reported a second-quarter earnings and revenue miss. Leerink responded by slashing its price target to $55 from $74, while Citi upgraded the equity to "buy" from "hold," finding positives from the hemophilia update. ONCE has now shed 73% since a July 9 all-time high of $96.59. 

Although the stock is on the short-sale restricted (SSR) list today, short sellers are likely cheering. The 5.34 million shares sold short represents 17% of ONCE's total available float, and 11.2 times the average daily trading volume.

OFIX Stock Tanks After Earnings, Slashed Guidance

Orthofix Medical stock is down 15.9% to trade at $52.01 after the company reported second-quarter revenue below analyst estimates, while also slashing its full-year guidance. Jefferies issued a price-target cut to $69 from $72 in response, and the stock is on track for its worst day since 2013. Nevertheless, OFIX scored a record high of $61.98 just yesterday, and still boasts a 16% lead year-over-year. Analysts are firmly entrenched in the bullish camp. All five of the brokerages covering OFIX rate it a "strong buy," while its average 12-month price target of $66.83 is a 29% premium to its current price.


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 


300x250 - Banner 3 - v1